Ertugliflozin

Drug Profile

Ertugliflozin

Alternative Names: MK-8835; PF-04971729; PF-4971729

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Developer Merck & Co; Pfizer
  • Class Antihyperglycaemics; Chlorobenzenes; Glycosides; Heterocyclic bicyclo compounds; Phenyl ethers; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus
  • Discontinued Hypertension

Most Recent Events

  • 10 Jun 2017 Efficacy and adverse event data from the phase III VERTIS MET trial in Type-2 diabetes mellitus released by Merck and Pfizer
  • 09 Jun 2017 Updated adverse events data from the phase III Vertis Mono trial in Type 2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 11 Apr 2017 Merck completes a phase III trial in Type-2 diabetes mellitus (Adjunctive Therapy) in USA, Czech Republic, Romania, Slovakia, Canada, Hungary and Lithuania (PO) (NCT01999218)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top